Lomond Therapeutics, Inc., a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological malignancies, announces the completion of a reverse merger transaction with Venetian-1 Acquisition Corp. and the closing of a $44 million private placement financing. Following the reverse merger, Venetian-1 Acquisition Corp. changed its name to Lomond Therapeutics Holdings, Inc. (“Lomond Therapeutics” or the “Company”), and will continue the historic and innovative business of Lomond Therapeutics, Inc.
Read the full article: Lomond Therapeutics Completes Reverse Merger and Closes $44M Private Placement //
Source: https://www.prnewswire.com/news-releases/lomond-therapeutics-completes-reverse-merger-and-closes-44-million-private-placement-302294982.html